These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12064312)
21. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD; Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173 [TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
23. A review of low-dose ritonavir in protease inhibitor combination therapy. Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760 [TBL] [Abstract][Full Text] [Related]
24. Failure of a ritonavir plus saquinavir-based rescue regimen precludes the use of protease inhibitors. Casado JL; Dronda F; Hertogs K; Antela A; Moreno S AIDS; 2000 Mar; 14(4):466-8. PubMed ID: 10770554 [No Abstract] [Full Text] [Related]
25. Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection. Ebrahim O; Hill A AIDS; 2005 Jan; 19(2):211-2. PubMed ID: 15668549 [TBL] [Abstract][Full Text] [Related]
26. Combined protease results continue to hold up. McGuire S Posit Aware; 1997; 8(1):15. PubMed ID: 11364089 [TBL] [Abstract][Full Text] [Related]
27. Combination study of Invirase and Norvir starting. AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633 [No Abstract] [Full Text] [Related]
29. Ritonavir and saquinavir combination: 12-week data at ICAAC. James JS AIDS Treat News; 1996 Oct; (No 256):3. PubMed ID: 11363880 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection. Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P; Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388 [TBL] [Abstract][Full Text] [Related]
31. Roche issues drug interaction warning. AIDS Alert; 2005 Apr; 20(4):48. PubMed ID: 15841532 [No Abstract] [Full Text] [Related]
32. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine. Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672 [TBL] [Abstract][Full Text] [Related]
34. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771 [TBL] [Abstract][Full Text] [Related]